Rhabdomyolysis in a patient receiving the combination of cerivastatin and gemfibrozil.
Straightforward reports of unusual drug experiences are included in this section. While selected references may be cited, the purpose of a Drug Experience report is not to present an extensive review of the literature. A related section, Grand Rounds, includes papers that are well-documented patient case reports with a thorough review of the important literature to help put the case in perspective. Authors should report serious adverse drug reactions to the FDA medical products reporting program (MedWatch). Such reporting will not jeopardize the chances that AJHP will publish manuscripts on the same drug reactions.
Bermingham
R P
RP
Fort Collins Family Medicine Residency Program, CO, USA.
Whitsitt
T B
TB
Smart
M L
ML
Nowak
D P
DP
Scalley
R D
RD
D002568:Certification / Q000592:standards; D004359:Drug Therapy, Combination; D005260:Female; D015248:Gemfibrozil / Q000009:adverse effects*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects*; D000960:Hypolipidemic Agents / Q000009:adverse effects*; D008875:Middle Aged; D010595:Pharmacists / Q000592:standards*; D011725:Pyridines / Q000009:adverse effects*; D012206:Rhabdomyolysis / Q000139:chemically induced*
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D011725:Pyridines; C086276:cerivastatin; D015248:Gemfibrozil